LEADING A NEW PARADIGM IN CARDIOVASCULAR DISEASE MANAGEMENT
Amarin Corporation is focused on a BOLD vision to stop heart disease from being a leading cause of death. Our lead commercial product, VASCEPA® (icosapent ethyl), creates a new paradigm in cardiovascular disease management and is positioned to address cardiovascular risk for millions of patients globally.
The efficacy and safety profile of VASCEPA, as demonstrated in the landmark REDUCE-IT® cardiovascular outcomes study, has been heralded as one of the most significant breakthroughs in preventative cardiovascular care since statin therapy was introduced nearly three decades ago. VASCEPA is supported by over 100 scientific publications and presentations and recommended for use in appropriate at-risk patients by leading medical societies from around the world, including the United States and Europe. The REDUCE-IT results stand in stark contrast to earlier generation drugs, the clinical studies of which failed to show reduction of persistent cardiovascular risk in their studied populations.
Company Received Final Positive Reimbursement Decision for VAZKEPA® by UK’s NICE in England & Wales Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Initiated Comprehensive Cost Redu...
Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022
Jul 20, 2022
DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s second...
NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales
Jul 13, 2022
-- Newly published final guidance by the National Institute for Health and Care Excellence (NICE) in the UK confirms its prior draft recommendation for the use of VAZKEPA® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascu...
REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo
Jun 30, 2022
-- Sub-Analysis Findings Support Prior Analyses that Eicosapentaenoic Acid (EPA) Level is The Major Determinant of Benefit in REDUCE-IT -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDA...